Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry

Respiratory Research

Manuel Monreal²  Antonio Riera-Mestre⁸  Ignacio Casado¹  Mar Martin³  José María Pedrajas⁵  Francisco Conget⁶  Joan Carles Sahuquillo⁷  Silvy Laporte⁴  Sara Quenet⁹  Laurent Bertoletti⁴ 

[1] Department of Pneumonology, Hospital Universitario Virgen de las Nieves, Granada, Spain;Department of Internal Medicine, Hospital Universitari Germans Trias I Pujol, Badalona, Spain;Department of Internal Medicine, Hospital Infanta Sofía, Madrid, Spain;Department of Therapeutic Medicine, CHU Saint-Etienne, Hôpital Nord, Saint-Etienne F-42055, France;Department of Internal Medicine, Hospital Clínico San Carlos, Madrid, Spain;Department of Pneumonology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain;Department of Internal Medicine, Hospital Municipal de Badalona, Barcelona, Spain;Department of Internal Medicine, Hospital Univesitari de Bellvitge - IDIBELL, Barcelona, Spain;Thrombosis Research Group, EA3065, University Saint-Etienne, Jean Monnet, Saint-Etienne F-42023, France

关键词: Venous thromboembolism;    Pulmonary embolism;    Prognosis;    Deep venous thrombosis;    Chronic obstructive pulmonary diseases;   

Others  :  793116
DOI  :  10.1186/1465-9921-14-75

 received in 2013-03-15, accepted in 2013-07-15,  发布年份 2013

【 摘 要 】

Background

Patients with chronic obstructive pulmonary disease (COPD) have a modified clinical presentation of venous thromboembolism (VTE) but also a worse prognosis than non-COPD patients with VTE. As it may induce therapeutic modifications, we evaluated the influence of the initial VTE presentation on the 3-month outcomes in COPD patients.

Methods

COPD patients included in the on-going world-wide RIETE Registry were studied. The rate of pulmonary embolism (PE), major bleeding and death during the first 3 months in COPD patients were compared according to their initial clinical presentation (acute PE or deep vein thrombosis (DVT)).

Results

Of the 4036 COPD patients included, 2452 (61%; 95% CI: 59.2-62.3) initially presented with PE. PE as the first VTE recurrence occurred in 116 patients, major bleeding in 101 patients and mortality in 443 patients (Fatal PE: first cause of death). Multivariate analysis confirmed that presenting with PE was associated with higher risk of VTE recurrence as PE (OR, 2.04; 95% CI: 1.11-3.72) and higher risk of fatal PE (OR, 7.77; 95% CI: 2.92-15.7).

Conclusions

COPD patients presenting with PE have an increased risk for PE recurrences and fatal PE compared with those presenting with DVT alone. More efficient therapy is needed in this subtype of patients.

【 授权许可】

   
2013 Bertoletti et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AMB, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E: International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet 2007, 370:741-750.
• [2]Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS medicine 2006, 3:e442.
• [3]Gershon AS, Warner L, Cascagnette P, Victor JC, To T: Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet 2011, 378:991-996.
• [4]Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, Bengel F, Brady AJB, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand J-P, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano J-LL, Andreotti F, et al.: Guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the European society of cardiology (ESC). Eur Hear J 2008, 29:2276-2315.
• [5]White RH: The epidemiology of venous thromboembolism. Circulation 2003, 107(23 Suppl 1):I4-I8.
• [6]Zielinski J: Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997, 52:43-47.
• [7]Bertoletti L, Mismetti P, Decousus H: The cloud of pulmonary embolism during COPD exacerbation. Thorax 2012, 67:177-178. author reply 178
• [8]Bertoletti L, Righini M: Adequate use of PE clinical prediction rule in COPD patients. Eur Respir J 2010, 37:218-219.
• [9]Bertoletti L, Mismetti P, Décousus H: Trends in cause-specific mortality in oxygen-dependent COPD: what about pulmonary embolism? Am J Respir Crit Care Med 2011, 184:1211-1212.
• [10]Bertoletti L, Quenet S, Mismetti P, Hernández L, Martín-Villasclaras JJ, Tolosa C, Valdés M, Barrón M, Todolí JA, Monreal M: Clinical presentation and outcome of venous thromboembolism in COPD. Eur Respir J 2012, 39:862-868.
• [11]Majoor CJ, Kamphuisen PW, Zwinderman AH, Ten Brinke A, Amelink M, Rijssenbeek-Nouwens L, Sterk PJ, Büller HR, Bel EH: Risk of deep-vein thrombosis and pulmonary embolism in asthma. Eur Respir J 2012. Epub ahead of print
• [12]Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S: Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
• [13]Baglin T, Douketis J, Tosetto A, Marcucci M, Cushman M, Kyrle P, Palareti G, Poli D, Tait RC, Iorio A: Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? a patient level meta-analysis. J Thromb Haemost 2010, 8(11):2436-2442.
• [14]Mismetti P, Baud J-M, Becker F, Belmahdi F, Blanchard P, Constans J, Couturaud F, Debourdeau P, Drouet L, Dumarcet N, Ferrari E, Galanaud J-P, Girard P, Hay B, Laporte S, Laroche J-P, Leizorovicz A, Liard F, Mahé I, Meyer G, Oger E, Parent F, Quéré I, Samama M: Guidelines for good clinical practice: prevention and treatment of venous thromboembolism in medical patients. J Mal Vasc 2010, 35:127-136.
• [15]Tzoran I, Saharov G, Brenner B, Delsart D, Román P, Visoná A, Jiménez D, Monreal M: Silent pulmonary embolism in patients with proximal deep vein thrombosis in the lower limbs. J Thromb Haemost 2012, 10:564-571.
• [16]Zvezdin B, Milutinov S, Kojicic M, Hadnadjev M, Hromis S, Markovic M, Gajic O: A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009, 136:376-380.
• [17]Pineda LA, Hathwar VS, Grant BJ: Clinical suspicion of fatal pulmonary embolism. Chest 2001, 120:791-795.
• [18]Ruíz-Giménez N, Suárez C, González R, Nieto JA, Todolí JA, Samperiz AL, Monreal M: Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thrombosis and haemostasis 2008, 100:26-31.
• [19]Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR: Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012, 141(2 Suppl):e419S-494S.
• [20]Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
• [21]Vitacca M, Bianchi L, Barbano L, Ziliani M, Ambrosino N: Effects of acute on chronic respiratory failure on hypercapnia and 3-month survival. Chest 2005, 128:1209-1215.
• [22]Carson JL, Terrin ML, Duff A, Kelley MA: Pulmonary embolism and mortality in patients with COPD. Chest 1996, 110:1212.
• [23]Laporte S, Mismetti P, Décousus H, Uresandi F, Otero R, Lobo JL, Monreal M: Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the registro informatizado de la enfermedad TromboEmbolica venosa (RIETE) registry. Circulation 2008, 117:1711-1716.
• [24]Spencer FA, Gore JM, Lessard D, Douketis JD, Emery C, Goldberg RJ: Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester venous thromboembolism study. Arch Intern Med 2008, 168:425-430.
• [25]Hartmann IJ, Hagen PJ, Melissant CF, Postmus PE, Prins MH: Diagnosing acute pulmonary embolism: effect of chronic obstructive pulmonary disease on the performance of D-dimer testing, ventilation/perfusion scintigraphy, spiral computed tomographic angiography, and conventional angiography. ANTELOPE study group. Am J Respir Crit Care Med 2000, 162:2232-2237.
• [26]Sohne M, Kruip MJH A, Nijkeuter M, Tick L, Kwakkel H, Halkes SJM, Huisman MV, Buller HR: Accuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism. J Thromb Haemost 2006, 4:1042-1046.
• [27]Shetty R, Seddighzadeh A, Piazza G, Goldhaber SZ: Chronic obstructive pulmonary disease and deep vein thrombosis: a prevalent combination. Journal of thrombosis and thrombolysis 2008, 26:35-40.
• [28]Murio C, Soler X, Pérez M, Calero G, Ruiz-Manzano J: Acute exacerbation of chronic obstructive pulmonary disease in primary care setting in Spain: the EPOCAP study. Ther Adv Respir Dis 2010, 4:215-223.
• [29]Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM: Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006, 28:523-532.
• [30]Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management and prevention of COPD. 2011. http://www.goldcopd.org/ webcite. Access on May, 5th 2013
• [31]Mismetti P, Rivron-Guillot K, Quenet S, Décousus H, Laporte S, Epinat M, Barral FG: A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism. Chest 2007, 131:223-229.